#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/6ebac4dddc69402cb8fdd90c746ff6ee572c95af/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET STATEMENT_GROUP = "Esther"

# Add statements below this comment

SET Citation = {"PubMed","Autophagy. 2018;14(12):2139-2154. doi: 10.1080/15548627.2018.1509607. Epub 2018 Sep 13.","30145931"}

SET Evidence = "At more mature ages (DIV14 - DIV21), MAPT localization is mainly
 found in the axons with only basal levels in the somatodendritic compartment,
 consistent with earlier findings [20]. "
SET MeSHAnatomy = "Neurons"
bp(GO:aging) -> p(HGNC:MAPT),loc(MESH:Axons))
bp(GO:aging) -| p(HGNC:MAPT),loc(MESH:Dendrites))
UNSET MeSHAnatomy

SET Evidence = "Our previous work showed that inhibition of either the proteasome or autophagy
in primary neurons induces pronounced neurotoxicity [23,24], making it impossible to address this
issue in conventional neuron cultures."
act(p(FPLX:Proteasome)) -| path(HBP:neurotoxicity)
bp(GO:autophagy) -| path(HBP:neurotoxicity)

SET Evidence = "  In order to determine the impact of protein degradation systems on the sorting of MAPT, we
sought to suppress their activity by treating neurons on the neuritic side of the MFCs with either
autophagy inhibitors, wortmannin [25] and bafilomycin A 1  [26], or with proteasomal inhibitors,
epoxomicin and lactacystin [27,28]."
a(CHEBI:wortmannin) -| bp(GO:autophagy)
a(CHEBI:"bafilomycin A1") -| bp(GO:autophagy)
a(CHEBI:epoxomicin) -| act(p(FPLX:Proteasome))
a(CHEBI:lactacystin) -| act(p(FPLX:Proteasome))

SET Evidence = "In
controls, the fraction of MAPT-containing dendrites on the neuritic side was low (~14%), but local
treatment with inhibitors of either autophagy (wortmannin [Fig. 3B], bafilomycin A 1  [Fig. S3A]) or
the proteasome (epoxomicin [Fig. 3C], lactacystin [Fig. S3B]) caused a pronounced 4-to 5-fold
increase of MAPT-containing dendrites (to levels of ~50-76%) (Fig. 3D)."
SET MeSHAnatomy = "Dendrites"
bp(GO:autophagy) -| p(HGNC:MAPT)
act(p(FPLX:Proteasome)) -| p(HGNC:MAPT)
UNSET MeSHAnatomy

SET Evidence = " Compared with the MAPT-free
dendrites of control neurons (Fig. S4A, 1.8±0.1), a substantial increase of SQSTM1 level
(21.1±0.9) was observed in MAPT-containing dendrites upon wortmannin treatment (Fig. S4B). "
SET MeSHAnatomy = "Dendrites"
a(CHEBI:wortmannin) -> p(HGNC:MAPT)
p(HGNC:MAPT) -> p(HGNC:SQSTM1)
UNSET MeSHAnatomy

SET Evidence = "Similarly, a dramatic elevation of ubiquitinated substrates (from 4.2±0.1 to 37±1) upon epoxomicin
treatment was detected in dendrites containing MAPT (compare Fig. S4E and Fig. S4F)."
SET MeSHAnatomy = "Dendrites"
a(CHEBI:epoxomicin) -> bp(GO:"protein ubiquitination")
UNSET MeSHAnatomy

SET Evidence = "MAPT in AD and other tauopathies is hyperphosphorylated [29] and the hyperphosphorylation has
been proposed to drive the missorting of MAPT. "
p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) positiveCorrelation path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) positiveCorrelation path(MESH:"Tauopathies")

SET Evidence = "In addition, it has been
reported that in cultured neurons, Aβ oligomers induce MAPT missorting into the somatodendritic
compartment, and the missorted MAPT is phosphorylated mainly at the 12E8 (p-S262/p-S356) and
AT8 (p-S202/p-T205) sites [6]."
a(HBP:"amyloid-beta oligomers") -> p(HGNC:MAPT, loc(MESH:Dendrites))
SET MeSHAnatomy = "Dendrites"
a(HBP:"amyloid-beta oligomers") positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,262))
a(HBP:"amyloid-beta oligomers") positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,356))
a(HBP:"amyloid-beta oligomers") positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,202))
a(HBP:"amyloid-beta oligomers") positiveCorrelation p(HGNC:MAPT, pmod(Ph,T,205))
UNSET MeSHAnatomy

SET Evidence = " Missorted
dendritic MAPT showed phosphorylation mainly at the 12E8 sites upon treatment with either the
autophagy inhibitor wortmannin (Fig. 4B; 57.2±9.4% dendrites) or the proteasomal inhibitor
epoxomicin (Fig. 4C, 62.9±7.4% dendrites) (Fig. 4A-C, quantification in Fig. 4D), but not at the
AT8 and the PHF1 (p-S396/p-S404) sites (Fig. S5, Fig 4D)."
SET MeSHAnatomy = "Dendrites"
a(CHEBI:wortmannin) positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,262))
a(CHEBI:wortmannin) positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,356))
a(CHEBI:epoxomicin) positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,262))
a(CHEBI:epoxomicin) positiveCorrelation p(HGNC:MAPT, pmod(Ph,S,356))
a(CHEBI:wortmannin) causesNoChange p(HGNC:MAPT, pmod(Ph,S,202))
a(CHEBI:wortmannin) causesNoChange p(HGNC:MAPT, pmod(Ph,T,205))
a(CHEBI:epoxomicin) causesNoChange p(HGNC:MAPT, pmod(Ph,S,202))
a(CHEBI:epoxomicin) causesNoChange p(HGNC:MAPT, pmod(Ph,T,205))
UNSET MeSHAnatomy

SET Evidence = " Thus, the dendritic and axonal MAPT are differentially
phosphorylated. Based on this observation, we can conclude that the dendritic MAPT degraded by
autophagy or proteasomal pathways is phosphorylated mainly at the 12E8 site. "
SET MeSHAnatomy = "Dendrites"
bp(GO:autophagy) -> deg(p(HGNC:MAPT, pmod(Ph,S,262)))
bp(GO:autophagy) -> deg(p(HGNC:MAPT, pmod(Ph,S,356)))
act(p(FPLX:Proteasome)) -> deg(p(HGNC:MAPT, pmod(Ph,S,262)))
act(p(FPLX:Proteasome)) -> deg(p(HGNC:MAPT, pmod(Ph,S,356)))
UNSET MeSHAnatomy

SET Evidence = " Our
previous study [23] had shown that trehalose induces autophagy in primary neurons and in an N2a
cell model of tauopathy, and efficiently reduces the level of MAPT and MAPT aggregation."
SET MeSHAnatomy = "Neurons"
a(CHEBI:"alpha,alpha-trehalose") -> bp(GO:autophagy)
a(CHEBI:"alpha,alpha-trehalose") -| p(HGNC:MAPT)
a(CHEBI:"alpha,alpha-trehalose") -| a(HBP:"Tau aggregates")
UNSET MeSHAnatomy

SET Evidence = " Trehalose treatment indeed
supressed the missorting of MAPT down to ~4±0.7% of dendrites, far less than the control level
(~16% of dendrites) (Fig. 5B)."
a(CHEBI:"alpha,alpha-trehalose") -| p(HGNC:MAPT, loc(MESH:Dendrites))

SET Evidence = "Treatment with rolipram (10 µM) on the
neuritic side for 24 h (Fig. 5C) supressed missorting of MAPT down to 4.5±0.4% dendrites, far
below the control level (20.5±5.6% dendrites) (Fig. 5D), thereby confirming the role of the
proteasome in degrading dendritic MAPT."
a(CHEBI:rolipram) -> act(p(FPLX:Proteasome))
a(CHEBI:rolipram) -| p(HGNC:MAPT, loc(MESH:Dendrites))

SET Evidence = "Previous studies had shown that the missorting of MAPT into dendrites can cause loss of spines
[6,7]."
p(HGNC:MAPT, loc(MESH:Dendrites)) -| a(MESH:"Dendritic Spines")

SET Evidence = "MAPT-free dendrites in
controls had a spine density of ~17 per 20-µm (17.2±0.5 per 20 µm) length, and there was a ~2-
fold decrease in spine density in the MAPT-containing dendrites in neurons treated with
wortmannin (7.4±1.0 per 20 µm) or epoxomicin (8.2±1.7 per 20 µm) (Fig. 6D). "
SET MeSHAnatomy = "Neurons"
a(CHEBI:wortmannin) -| a(MESH:"Dendritic Spines")
a(CHEBI:epoxomicin) -| a(MESH:"Dendritic Spines")
UNSET MeSHAnatomy

SET Evidence = "Conversely, treatment with protein translation inhibitors, cycloheximide or anisomycin, alone (Fig.
S8A and B) almost completely abrogated MAPT missorting (schematic in Fig. 2E). These results
suggest that the dendritic MAPT is locally generated. "
a(CHEBI:cycloheximide) -| bp(GO:translation)
a(CHEBI:"(-)-anisomycin") -| bp(GO:translation)
a(CHEBI:cycloheximide) -| p(HGNC:MAPT, loc(MESH:Dendrites))
a(CHEBI:"(-)-anisomycin") -| p(HGNC:MAPT, loc(MESH:Dendrites))

SET Evidence = "This observation, together with local synthesis of MAPT protein, confirms that Mapt mRNA
is present in dendrites and is actively translated."
r(HGNC:MAPT, loc(MESH:Dendrites)) -> p(HGNC:MAPT, loc(MESH:Dendrites))
